Drug Type Biosimilar, Monoclonal antibody |
Synonyms Dupilumab Biosimilar (Samsung Bioepis Co., Ltd.), 度普利尤单抗生物类似药(Samsung Bioepis Co., Ltd.), SB34 |
Target |
Action inhibitors |
Mechanism IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Immune System Diseases | Preclinical | South Korea | 01 Mar 2026 |






